Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins by unknown
Biological Activities ofPeptides and Peptide
Analogues Derived from Common Sequences Present
in Thrombospondin, Properdin, and Malarial Proteins
George PTuszynski,* Vicki L. Rothman,* Alan H. Deutch,t Bruce K. Hamilton,$ and Jacob Eyal$
*Department ofMedicine, MedicalCollege ofPennsylvania, Philadelphia, Pennsylvania 19129; andW. R. Grace&Co.-Conn.,
Washington Research Center, Columbia, Maryland 21044
Abstract. Thrombospondin (TSP), a major platelet-
secreted protein, has recently been shown to have ac-
tivity in tumor cell metastasis, cell adhesion, and plate-
let aggregation. The type 1 repeats of TSP contain two
copies of CSVTCG and one copy of CSTSCG, per
each of the three polypeptide chains of TSP and show
homology with peptide sequences found in a number
of other proteins including properdin, malarial circum-
sporozoite, and a blood-stage antigen of Plasmodium
falciparum. To investigate whether these common se-
quences functioned as a cell adhesive domain in TSP,
we assessed the effect ofpeptides corresponding to
these sequences and an antibody raised against one of
these sequences, CSTSCG, in three biological assays
which depend, in part, on the cell adhesive activity of
TSP These assays were TSP-dependent cell adhesion,
T
HROMBOSPONDIN (TSP)l is a 450,000-dalton glyco-
protein secreted by platelets inresponse to suchphys-
iological activators as thrombin andcollagen (9). TSP
comprises 3% of the total platelet protein and 25% of the
total platelet-secreted protein (26). Although the precise
biological role of TSP has yet to be fully established, it is
generally accepted that TSP plays amajor role incell adhe-
sionand cell-cellinteractions. For example, TSP was found
topromotethe cell-substratum adhesion ofavarietyofcells,
including platelets, melanoma cells, muscle cells, endothe-
lial cells, fibroblasts, and epithelial cells (24). In addition,
cells with very specialized functions such as keratinocytes
(27) and osteoblasts (16) attach to TSP. Finally, TSP pro-
motes the irreversible aggregation of platelets (23).
Thrombospondin has been postulated to play a role in
malarial infection induced by only one strain of malaria,
Plasmodiumfalciparum, and tumor cell metastasis induced
by small cellcarcinoma andmouse sarcoma. During malar-
ial infection, TSPpromotes adhesion ofparasitized red cells
to endothelial cells (15) and during tumor cell metastasis
1. Abbreviations used in this paper: KLH, keyhole limpet hemocyanin;
PRP, platelet-rich plasma; TSP, thrombospondin.
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platelet aggregation, and tumor cell metastasis. We
found that a number of peptides homologous to CSV
TCG promoted the adhesion of a variety ofcells includ-
ing mouse B16-F10 melanoma cells, inhibited platelet
aggregation and tumor cell metastasis, whereas control
peptides had no effect. Anti-CSTSCG, which specifi-
cally recognized TSP, inhibited TSP-dependent cell ad-
hesion, platelet aggregation, and tumor cell metastasis,
whereas control IgG had no effect. These results sug-
gest that CSVTCG and CSTSCG present in the type I
repeats function in the adhesive interactions of TSP
that mediate cell adhesion, platelet aggregation, and
tumor cell metastasis. Peptides, based on the structure
of these repeats, may find wide application in the treat-
ment of thrombosis and in the prevention of cancer
spread.
TSPpromotesadhesion ofmouse sarcomacellstothevascu-
lar bed (20) and expression ofthe malignant phenotype of
small cellcarcinoma(3). Furthermore, TSP hasbeenshown
to share sequence homologies with malarial circumsporo-
zoiteproteins (8), which function in thecellular adhesion of
the sporozoite stageofthe malarial parasite. Recently, Rob-
son et al. (17) further notedthatthe most significant homol-
ogy is basedaround theconsensus sequence WSPCSVTCG,
whichispresentinthreehomologouscopies inTSP(referred
toas thetype 1 repeats; 11), sixcopies inproperdinandone
copy each in all ofthe malarial circumsporozoite proteins
studied to date including the blood-stage antigen ofP . fal-
ciparum. Based ontheevidence described above, wepostu-
lated that the sequences contained in the type 1 repeats of
TSP must be playing a very fundamental role in ligand-re-
ceptor interactions mediating cellular adhesion. Therefore
totestthishypothesis,thecelladhesive activities ofsynthetic
peptides corresponding to these sequences were evaluated
for activity in TSP-dependent cell-substratum adhesion as-
says and in the biological processes of platelet aggregation
andtumorcellmetastasis, whichinpartdepend ontheadhe-
sive activities ofTSP. In the present study we demonstrate
that these sequencesmediateTSP-dependent adhesive inter-
209actions andplay a role in platelet aggregation andtumorcell
metastasis. Our results confirmthe recent studies of Rich et
al. (14) andPrater etal. (13) whoshowed that sequencescon-
taining VTCG can function as cell recognition sites.
Materials andMethods
Materials
All reagents, unless specified otherwise, were purchased from Sigma
Chemical Co. (St. Louis, MO). Tissue culture supplies were purchased
from ICN Flow (Irvine, CA).
CellAdhesion Assay
The cell adhesion assay was performed as previously described (22).
Briefly, 2 jig ofeach peptide orTSP in50 id Hepes-buffered saline, pH 7.35
wasdriedunder nitrogen inthewellsofmicrotiterplates. 100 pl ofa suspen-
sion containing 2 x 103 cells/ml in Hepes-buffered saline, pH 7.35, con-
taining 100 pM MnC12, and 5 mM glucose was incubated in the peptide-
coated well for 30-60 min, non-adherent cells removedby aspiration, wells
washed and total adherent cells determinedby protein assay. Cells adhering
to BSA-coated wells were 2-5% ofTSRadherentcells and considered back-
ground.
Direct Enzyme-linked ImmunoadsorbentAssay
ELISA assays were performed as previously described (25). Briefly, micro-
titer plates were coated with 2 pg of TSP or 2 wg peptide and blocked with
1% BSA for 1 h. Wells were incubatedfor 1 h with 50 pl ofvarious dilutions
ofthe firstantibody in 10 mM phosphatebuffer, pH 7.4, containing 150mM
NaCl, and 0.05% Tween-20 (PBST). Wells were then washed three times
in PBST and incubated for 1 h with 50 Al ofa 1:800 dilution in PBST of
alkalinephosphatase coupled rabbitanti-goat 4G. Wells were washedthree
times with PBST followed with three washes of PBST buffer containing
no Tween-20 and treated with 50 pl of alkaline phosphatase substrate solu-
tion (1 mg/ml ofp-nitrophenylphosphate in 0.10 M glycine, pH 10.4, con-
taining 1 mM ZnC12 and 1 MM MgC12). After 30 min, color development
was stopped by the addition of 5 Al of 1 N NaOH and absorbances deter-
mined at 405 run.
PeptideAntibody
CSTSCG was coupled to maleimide activated keyhole limpet hemocyanin
(KLH) according to the instructions provided with the Pierce Imject Acti-
vated Immunogen Conjugation Kit (Pierce Chemical Co., Rockford, IL).
Approximately 4 mg of peptide was coupled to 2 mg of KLH. A goat was
injected subcutaneously with 1 mg ofpeptide-protein conjugate suspended
in complete Freund's and boosted with two additional injections of500 jig
ofpeptide-protein conjugate in incomplete Freund's adjuvantthree and five
weeks after the first injection. Goat immunization and collection ofserum
was accomplished commercially through Hazelton Research Products, Inc.
(Denver, PA).
Polyclonal anti-CSTSCG was affinity purified on Sepharose-KLH, fol-
lowed by Sepharose-TSP Briefly, IgG prepared by ammonium sulfate
precipitation of 100 ml of anti-sera was dissolved in 50 nil of Hepes-
buffered saline, pH 7.35 (column buffer), and passed over a 5 ml column
of Sepharose containing 15 mg of coupled KLH which was previously
equilibrated withcolumn buffer. The flow-through fraction waspassed over
a 1 ml column of Sepharose containing 2 mg of coupled TSP . The TSP
columnwas then washedwith 10 ml ofcolumnbuffer and eluted with 0.1 M
sodium citrate buffer, pH 2 .7. 1-ml fractions were collected in tubes contain-
ing 50 Al of 1 M Tris base to neutralize the final solution. Protein fractions
were pooled, concentrated, and assessed foranti-TSP activity by ELISA and
Western immunoblot analysis.
Platelet Aggregation
Platelet aggregation was performed as previously described (23). Briefly,
blood obtained from healthy volunteers was centrifuged to obtain platelet-
rich plasma (PRP). The stirred PRP was aggregated with ADP in the pres-
ence and absence of peptide and the extent of aggregation monitored with
a Chrono-log Aggregometerby measuring the increase in light transmission
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Table1. CSVTCG and Related Sequences Found
in Different Proteins and Encoded by cDNA
The single-letter abbreviations for the amino acid residues are A, Ala; C, Cys;
D, Asp; E, glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N,
Asti; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
* Encoded by cDNA and predicted to be in one of the six possible regions of
the respective gene.
as a function oftime. Collagen-induced platelet aggregation was performed
on washed human platelets isolated as previously described (21). Briefly,
platelets preincubated for 1 min with peptide were stirred with collagen at
a final concentration of 5 pg/ml and the aggregation monitored optically
with an aggregometer.
Synthetic Peptides
Synthetic peptides were purchased from Multiple Peptide Systems, (San
Diego, CA). The peptides were >95 % pureasassessed by HPLC and stored
under argon at -20*C to prevent oxidation. Solutions were prepared im-
mediately before use. For cell adhesion experiments, 2 kg of peptide was
adsorbed on the surface ofmicrotiter wells by drying under nitrogen 50 kl
of a 40 pg/ml solution of peptide dissolved in Hepes-buffered salii.e. pH
7.35. In all other experiments, peptide stock solutions were 5-10 mg/ml iii
Hepes-buffered saline, pH 7.35. The free thiol content ofthe peptide solu-
tions was routinely checked spectrophotometrically by titration w;*',
Ellman's reagent (Pierce Chemical Co., Rockford, IL). Peptides containing
free thiols were >90% in the reduced form. Peptides used for metastasis
assays were endotoxin free as assessedby enzyme-linked immunoassay and
were found non-toxic to cells during 24 h of culture.
TSP Purification
TSP was purified from Ca+2 ionophore À231ß7-activated platelets as previ-
ously described (26).
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Figure 1. Representation of CSVTCG sequences in TSP . Sequence
data obtained from reference 11.
Protein Sequence Reference
TSP CSTSCG, CSVTCG 11
Circumsporozoite
protein CSVTCG 4
Trap CSVTCG 17
Properdin CSVTCG 7
Glycoprotein 13
equine Herpes virus CSVTCG 1*
Cytomegalovirus
HHLF5 protein CSVTCG 29*
Gene 53 protein
Varicella-zoster virus CSVTCG 6*
Rat liver
apolipoprotein A-I CSVTCG 12*
Nitrate reductase CSVTCK 2Table H. Attachment ofVarious Cells to MicroliterPlates
Coated with CSVTCG and Its Homologous Analogues
Percent of TSP-adherent cells
Tbmor Cell Metastasis Assay
Peptides CSVTCR and CSTSCR had the terminal carboxyl group in the amide
form . Peptide C(Acm)SVTC(Acm)G contained acetaminomethyl blocked cys-
teine residues (28) . The results are presented as percent of number of cells ad-
herent to TSP-coated microtiter wells . Results of representative experiments
are above . Percent TSP-adhesion was calculated as the number of cells adher-
ing to the test compound divided by the number of cells adhering to TSP times
100 . By definition adhesion to TSP is 100% and represents 500 adherent cells
per min' . The number of adherent cells used to calculate % adhesion was
the mean of triplicate determinations with standard deviations ranging from
1 to 5% .
Tumor cell metastasis wasperformed as previously described (20) . Briefly,
B16-F10 melanoma cells were cultured inDME containing 10% FCS. Cells
were harvested in log phase with EDTA, washed, and suspended in Hepes-
buffered saline . Each peptide was either coinjected with 1 x 105 B16-F10
Tuszynski et al . Biological Activities of TSP Type 1 Repeats
mouse melanoma cells into a lateral tail vein of a C57BL/6 mouse or seri-
ally injected into separate lateral tail veins. In some experiments cells were
injected first and then peptide . Animals were sacrificed 14 d later and lung
tumor colonies were counted . Cell viability atthe beginning and end of the
metastasis experiments was >90% as measured by trypan blue exclusion .
WesternImmunoblotting
Anti-CSTSCG antibody was characterized by Western immunoblotting
using Pharmacia's Phast gel electrophoresis system . Approximately 100 ng
of TSP was separated under reducing conditions on an 8-25% polyacryl-
amidegradient SDS gel. Gels wereeither silver stained orthe proteins were
electrophoretically transferred onto nitrocellulose paper. The paper was
then blocked with 1% BSA in PBS-T and treated with 5 pg/ml of affinity
purified goat anti-CSTSCG for 1 h, washed with PBS-T, developed accord-
ing to the instructions provided with the VECTASTAIN ABC immuno-
peroxidase system, Vector Laboratories (Burlingame, CA) .
Results
TSRdependent Cell Adhesion
We chose to study CSVTCG and its related analogues be-
cause this sequence was present in two identical copies in the
thrombospondin molecule . In addition, a computer search
revealed that sequences analogous to this hexapeptide se-
quence were present or encoded by the cDNA of a number
of apparently unrelated proteins suggesting some common
function perhaps in ligand recognition (Table I) . Further-
more, preliminary experiments showed that peptides derived
fromTSP sequences upstream ofCSVTCG containing the se-
quence, WSP, had no activity in our adhesion assay (data not
shown) . In TSP, CSVTCG, and the related sequenceCSTSCG
occur in the type 1 repeats present in region E ofthe molecule
which contains domains that interact with collagen and fibro-
nectin (5), important adhesive extracellular matrix mole-
cules (Fig . 1) . Peptide CSVTCG and its analogues promoted
Figure 2. Adherent mouse B16-
F10 mouse melanoma cells .
Mouse B16-FIOmelanomacells
were allowed to adhere for 30
minto microtiterplates coated
with TSP, FN, and CSVTCR .
Cells were photographed at a
magnification of 300x using
Hoffman interference micros-
copy.
Compound
B16-F10
mouse
melanoma
Cell type
A549
human lung
adenocarcinoma
Bovine aortic
endothelial
cells
Rabbit
smooth
muscle
ANKHYF 8 10 0 17
VCTGSC 2 8 3 17
TCVCGS 10 10 6 8
CSVTCG 40 29 49 44
CSTSCG 37 23 39 22
Cyclic
CSVTCG 30 29 25 43
C(Acm)SV-
TC(Acm)G 32 44 22 46
CSVTCR 92 90 99 159
CSTSCR 39 104 65 82
CSVTCG 92 79 80 82C
c O
É
C
L
Control VCTGSC 111 ANKHYF CRVTCG C(ACM)SVT- CSVTCGR-NB2
C(Acm)G-NH,
Time (min)
the attachment ofa variety ofcells including both normal and
tumor cells (Table 1I) . For example, B16-F10 mouse mela-
noma cells, A549 human lung adenocarcinoma cells, rabbit
smooth muscle cells, and bovine aortic endothelial cells at-
tached to the thrombospondin sequence CSVTCG 29-49%
compared toTSP. In contrast, the control peptides, TCVCGS,
VCTGSC, and ANKHYF, displayed little or no significant
cell adhesive activity . In addition, derivatives ofCSVTCG,
cyclic CSVTCG, in which the two cysteine residues are
joined by disulfide residues to form a five-membered ring
structure, and C(Acm)SVTC(Àcm), in which C(Acm) is an
acetamidomethyl-blocked cysteine residue, promoted attach-
ment of the four cell lines approximately to the same extent
as CSVTCG . The substitution ofR forG to yield CSVTCR
displayed the greatest cell attachment activity of90-159% as
compared to TSP . The peptide CSTSCR obtained by sub-
stituting R for G in CSTSCG, a sequence present in the
type 1 repeats of TSP, also displayed a high adhesive activity
of 39-104% as compared toTSP . Thehuman cancer cell line
A549 adhered to this peptide to the same extent as TSP In
addition, the morphological appearance of B16-F10 mela-
noma cells on CSVTCR resembled that observed on fibro-
nectin, displaying a flattened morphology with numerous
pseudopodia (Fig . 2) . Similar morphological changes on
CSVTCR were observed for the other cells listed in TableH .
Itis possible that substitution ofarginine for glycine or serine
could increase the capacity of these peptides to bind cell asso-
ciated glycosaminoglycans and thereby increase their adhe-
sive activity. In support of this hypothesis is the observation
that CRVTCG possessed heparin binding activity whereas
CSVTCG did not (data not shown) .
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PlateletAggregation
Peptide CSVTCG and its analogues inhibited ADPinduced
platelet aggregation (Fig . 3) . In contrast, the control pep-
tides, ANKHYF and VCTGSC, displayed no activity. The
active peptides specifically inhibited the formation of the
ADP-induced second wave of platelet aggregation as indi-
cated by the decreased extent of light transmission observed
during the later stages of platelet aggregation shown in Fig.
3 . The lower extent of light transmission observed at later
times during aggregation in the presence of active peptides
was due to the formation ofsmaller platelet clumps (Fig. 4) .
For example, Fig . 4 shows that in the absence of agonist no
platelet clumps are formed, in the presence of agonist and
buffer macroaggregates formed comprisingmore than 1,000
platelets per clump, while in the presence of agonist and
CSVTCG only 10-50 platelets per clump were generated .
The effect of peptides on aggregate size could not be attrib-
uted to an inhibition ofplatelet secretion since serotonin re-
lease was not affected (data not shown) . These peptides also
inhibited platelet aggregation induced by collagen . For ex-
ample, Table III shows the percent inhibition observed for
two representative peptides, CSTSCG and CSVTCG . At the
highest dose tested, CSTSCG and CSVTCG inhibited aggre-
gation by 96 and 100%, respectively. These results suggest
that the peptide CSVTCG and its homologous analogues in-
hibit platelet aggregation by antagonizing those adhesive in-
teractions that mediate platelet aggregation .
?}imor Cell Metastasis
Peptides CSVTCG, CSTSCG, and cyclic CSVTCG, when
212
Figure 3 . The effect of CSV
TCG on ADP-induced platelet
aggregation . Human platelet-
rich plasma was aggregated
with 4 1AM ADP in the pres-
ence ofvarious peptides . (Top)
Platelets were aggregated in
the presence of 500 ug/ml
of peptide . (Bottom) Platelets
were aggregated in the pres-
ence of increasing concentra-
tions of CSVTCG shown in
parentheses . For comparison,
platelets were also aggregated
in the presence of GRGDS,
a peptide that totally inhibits
aggregation . Aggregations were
monitored on a Chrono-log
aggregometer.Figure 4 . Aggregated platelets in the presence and absence ofCSVTCG. Unaggregated platelets or platelets aggregated with 4 /AM ADP
for 5 min in the presence of buffer or 500 /g/ml CSVTCG were photographed at 300 times magnification using Hoffman interference
microscopy. (A) Unaggregated platelets ; (B) aggregated platelets in the absence ofCSVTCG ; (C) aggregated platelets in the presence of
CSVTCG.
co-injected i.v. with 105 B16-F10 mouse melanoma cells,
inhibited formationof lung tumor metastases by42-85% in
pathogen-free C57BL/6 mice (Table IV) . Peptides had no
effect on the viability of B16-F10 cells in vitro . Cell growth
in culture was not inhibitedby peptides at concentrations as
high as 1 mg/ml after 24 h and cells were >90% viable as
measured by trypan blue exclusion (data not shown) . In addi-
tion, peptide solutions contained no endotoxin. To further
rule outadirect effect ofpeptides on the metastatic potential
of the cells, peptides were i.v. injected into one lateral tail
vein followed by i.v. injection of tumor cells into the other
lateral tail vein (Fig . 5) and the reverse i.e. tumor cells fol-
lowed by peptide (Table IV) . In each case, inhibition of tu-
mor cell metastasis of 39-75% was observed . In contrast,
the control peptides, ANKHYF and TCVCGS, had no
significant effect on lung tumor colony formation, since the
number of tumor colonies in thepresence of these peptides
Table IIL The Effect ofCSVTCG and CSTSCG on
Collagen-induced Platelet Aggregation
Concentration
Platelet aggregations were performed as described in Materials and Methods.
Percent inhibition was calculated as the maximal increase in light transmission
units of buffer control minus that in the presence oftest compound times 100.
The experiment shown represents a typical experiment obtained from a single
normal blood donor. Qualitatively similar results were obtained from two other
normal donors .
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was not statistically different from that observed in buffer
control, p < 0.01. These results indicated that peptide
CSVTCG and its homologous analogues have anti-tumor
metastasis activity.
Table IV . Effect ofSynthetic Peptides on B1 6-F10Mouse
Melanoma Cell Metastasis
Treatment
Buffer
TCVCGS
Number of lung tumors
(mean t SEM)
￿
Percent inhibition
Injection of cells followed by peptide
74 t 24
￿
8
Cyclic
CSVTCG
￿
35 t 10
￿
56
CSTSCG
Buffer
49 t 12
￿
39
80 f 12
￿
0
CSVTCG
￿
46 t 5
￿
42
CSTSCG
￿
12 f 2
￿
85
Cyclic
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Coinjection of cells and peptide
CSVTCG
￿
28 t 3
￿
65
Each peptide (1 mg)was either coinjected with 1 x 10 5 B16-F10 mouse mela-
noma cells into a lateral tail vein ofa C BL/6 mouse or serially injected into
separate lateral tail veins, cells than peptide. Animals were sacrificed 14 d later
and lung tumor colonies were counted . Each treatment group consisted of five
animals . All metastasis experiments were repeated two to three times, showing
qualitatively similar results . Representative experiments are shown .
Compound (Wg/ml) Percent inhibition
ANKHYF 500 0
CSVTCG 500 100
CSTSCG 500 96
CSVTCG 50 32
CSTSCG 50 26Figure5 . The effect ofsynthetic peptides on
tumor cell metastasis . 1 mg of peptidewas
injected into one lateral tail vein of mice
followed immediately by the injection of 1.0
x 105 B16-F10mouse melanoma cells into
the second lateral tail vein . Cells were har-
vested in EDTA and suspended in Hepes-
buffered saline solution, pH 7.35, and pep-
tides were dissolved in the same buffer.
Mice were sacrificed after two weeks and
the lung tumor colonies counted . Treat-
ment groups contained five animals . The
error bars represent the standard error of
the mean . The photographs below the bar
graphs show three lungs from each treat-
ment group. The black spots aremelanoma
tumors. All metastasis experiments were
repeated two to three times, showing quali-
tatively similar results . Representative ex-
periments are shown .
Figure 6. Analysis of anti-
CSTSCG by western blotting.
Purified TSP was separated
under reducing conditions on
an 8-25% polyacrylamide
SDS-gelusing the Pharmacia
Phast System. Proteins were
then electrophoretically trans-
ferred to nitrocellulose and ei-
ther stained with silver or in-
cubated with either 7.6 gg/ml
solutions of affinity purified
goatanti-CSTSCGorgoatIgG
inTris-buffered saline contain-
ing 0.05% Tween 20. Bound
antibodywas detectedwithpe-
roxidase-coupled rabbit anti-
goat IgG . Lane A, TSPstained
with antibody ; lane B, TSP
stained with controlIgG ; lane
C, TSP silver stained ; lane D,
silver stained molecular weight
standards .Table V. Immunoreactivity ofGoat Anti-CSTSCGAntibody
The Oxidative StateofPeptides
AntipeptideAntibody
_w
é
é r
0
a
E
i
700-
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t00
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Goat IgG
Anti-CSTSCG
Immunoreactivity ofanti-CSTSCG was measured by direct ELISA as described in Materials and Methods. Final antibody and IgGconcentrations were 22 jug/ml.
The average of three determinations is given t the standard deviation. Rat and mouse TSP was purified by the same procedure used to purify human TSP.
The oxidative state of the cysteine residues did not appear to
influence the cell-substratum adhesive properties ofthe pep-
tides examined in this study. For example, C(Acm)SVTC-
(Acm)G, containing cysteine residues blocked with acetami-
domethyl groups, which prevent inter- and intra-disulfide
bond formation, and cyclic CSVTCG, which contains the
two cysteine residues linked by disulfide bonds, both sig-
nificantlypromoted adhesion (Table II). Similarly, C(Acm)-
SVTC(Acm)G inhibited platelet aggregation (Fig. 3) and cy-
clic CSVTCG prevented tumor cell metastasis (Fig. 5, Table
IV). The sequence CSVTCG probably exists in TSP with the
cysteine residues disulfide-linked, since the three free thiol
groups present in TSP can appear anywhere in positions 687-
1149 (19), while residues CSTSCG are contained in posi-
tions 373-378, and CSVTCG are contained in residues 429-
434 and 486-491 of TSP
Tb further establish that the type 1 repeats of TSP-promoted
cell adhesive interactions, a polyclonal antibody to CSTSCG
was prepared. The antibody was raised ina goatby immuniz-
t= TV
- FN
Control Anfl-KLH Antl-CSTSCG
Figure 7 . Theeffect of anti-CSTSCG on B16-F10 melanoma cell ad-
hesion. Wells ofan eight-well glass tissue culture slide were coated
with TSP and fibronectin as previously described (24). Protein-
coated surfaces were then treated with buffer or with 5 ul of a 500
j,g/ml solution ofeither affinity purified anti-CSTSCG or anti-KLH
for30 min andcell adhesion performedas described (24). Solidbars
represent adhesion to fibronectin and open bars represent adhesion
to TSP. Treatment groups are designatedbeloweach set of bars. Er-
ror bars represent the standard deviation of triplicate samples. The
experiment shown is a representative of two separate experiments
that gave qualitatively similar results.
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Absorbance (405 nm)
ing the animal with peptide coupled to KLH. The final anti-
body was adsorbed with KLH and affinity purified on a TSP-
Sepharose column. The affinity purified antibody recognized
the 180,000 dalton chain of TSP (Fig. 6). In addition, by
means of direct immunoadsorbent assay, the antibody re-
acted with CSTSCG, CSVTCG, humanTSP, rat TSP, mouse
TSP, but not with BSA (Table V). When adsorbed TSP was
treated with this antibody and tested for cell adhesive activ-
ity, 70% of the cell adhesive activity of TSP was inhibited
whereas the same antibody had no effect on fibronectin-
mediated adhesion (Fig. 7). In addition, anti-KLH antibod-
ies had no effect on TSP-mediated adhesion. Anti-CSTSCG
at a concentration range of 33-70 pg/ml inhibited ADP-
induced platelet aggregation and tumor cell metastasis by
73-80% (Fig. 8). These results further support the conclu-
sion that CSTSCG is a cell adhesive domain in TSP and pro-
vide strong evidence that peptides homologous to the type
1 repeats of TSP function in cell adhesive mechanisms.
Discussion
Our data suggest that the conserved sequences, CSVTCG
and CSTSCG, present in the type 1 repeats of TSP function
as adhesive domains that mediate the cell interactions in-
volved in platelet aggregation and tumor cell metastasis.
During the course ofthis work Rich and co-workers(14) pub-
lished a study demonstrating that 18-20 amino acid peptides
containing the sequence VTCG found in the malarial cir-
cumsporozoite protein and in the protein from the sexual
stage ofP, falciparum promoted the attachment of a variety
of human hematopoietic cell lines and two small cell carci-
noma cell lines. Our studies are in agreement, since we find
that peptides homologous to CSVTCG, which contain the
VTCG sequence, promoted the attachment of a variety of
cells including mouse melanoma cells and human lung ade-
nocarcinoma cells. Shortly afterwards, Prater and co-workers
(13) published a study showing that synthetic peptides corre-
sponding to residues 424-42 and 481-99 of TSP promoted
attachment of G361 cells but a peptide corresponding to
residues 368-86 was inactive. The active peptides contained
the sequence ASVTAG in place of CSVTCG and the in-
active peptide contained the sequence ASTSAG in place of
CSTSCG. The authors state that substitution of alanine for
cysteine results in approximately a twofold loss in adhesive
activity due to a lower coating efficiency of the alanine-
containing peptide. Another difference between the work of
Prater et al . (13) andthe present study is that theirmAb A4.1,
the epitope for which localizes to the region of TSP contain-
ing the type 1 repeats, had no effect on platelet aggregation,
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BSA Human TSP Rat TSP Mouse TSP CSTSCG CSTTCG
0.037 0.063 0.042 0.053 0.048 0.043
f 0.004 t 0.002 t 0.002 t 0.004 t 0.002 t 0.002
0.008 0.713 0.818 0.169 0.135 0.186
t 0.006 t 0.062 t 0.039 t 0.009 t 0.030 t 0.025c
c 0
w
m
c
as
l-
t
Time (min) -
A
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whereas our anti-CSTSCG antibody inhibited platelet aggre-
gation. A possible explanation for this difference is that A4 .1
may not be directed against the same epitope as our antipep-
tide antibody. In our study, both CSTSCG and CSVTCG
promoted cell adhesion suggesting that all three type 1 re-
peats per each of the three chains of TSP function as cell
adhesive domains. The oxidative stateofthe cysteine groups
did not appear to play a major role in the adhesion reac-
tion since peptides having the cysteines blocked or oxidized
promoted adhesion. For example, we found that peptide
CSVTCG slowly oxidized in solution forming large inter-
molecular linked multimers that migrated with apparent mo-
lecular weights of 2,000 on SDS-gels. However, freshly pre-
pared solutions were stable for at least 2 h.
Our work further suggests that these sequences may play
an important role in the adhesive interactions mediated by
TSP in the process of platelet aggregation and tumor cell
metastasis. For example, we show that ADP-induced platelet
aggregation is inhibited by CSVTCG and its homologous
peptides. The platelet aggregates formed in the presence of
these peptides are small and reversible suggesting that these
compounds do not effect platelet fibrinogen binding but
rather TSP platelet binding which has been shown to pro-
mote the formation of large irreversible aggregates (23). We
think these peptides are inhibiting collagen-induced platelet
aggregation by interfering with platelet collagen interaction.
Further work is needed to clarify the mechanisms by which
these peptides inhibit ADP and collagen-induced platelet
aggregation .
We previously showed that TSP promoted the attachment
of B16-F10 melanoma cells and that when intravenously in-
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Figure 8. The effect of anti-
CSTSCG on platelet aggrega-
tionand tumor cell metastasis.
Panel A, human platelet-rich-
plasma was aggregated in the
presence of either 70 Aglnd of
affinity purified anti-CSTSCG
or 70 Aglml non-immune con-
trol IgG. Panel B,100,ug ofei-
ther control IgG or 100 hg of
affinity purified anti-CSTSCG
was co-injected with 1.0 x 105
B16-F10 mousemelanomacells
intothe lateraltail veinofmice
(6 animals per group). Cells
were harvested in EDTA and
suspended in Hepes-buffered
saline solution, pH 7.35, and
antibodiesdissolvedinthe same
buffer. Antibodies had no ef-
fecton theviability ofthe cells
as assessed by trypan blue ex-
clusion. Mice were sacrificed
after two weeks and the lung
tumor colonies counted. The
error bars represent the stan-
dard error of the mean. All
metastasis experiments were
Control
￿
Antl-CSTSCG
￿
repeated two to three times,
showing qualitatively similar
B
￿
results. Representative experi-
ments are shown.
jected with tumor cellsin syngeneic mice, TSP promoted the
arrest of B16-F10 cellsin the lung with a subsequentincrease
in the formation oflung tumor colonies as compared to con-
trols (20). In these early studies we postulated that endoge-
nous TSP as well as exogenously added TSP promoted
metastasis formation. The results of the present studies sup-
port the hypothesis that endogenous TSP mediates tumor cell
metastasis in this model system. For example, the TSP-
peptides, CSVTCG, and its homologous analogues, were
found to inhibit metastasis by 39-85 % . More inhibition was
found when peptides were coinjected with cells or injected
before injection of cells than when cells were injected fol-
lowed by peptide. One interpretation of these results is that
the peptides, structurally similar or identical to the adhesive
domain of mouse TSP, antagonize the cell adhesive activity
of endogenous TSP which, in part, mediates the arrest oftu-
mor cells in the lung. We propose that endogenous TSP pro-
motes tumor cell metastasis by providing circulating tumor
cells with a provisional extracellular matrix from which they
can escape the circulation and invade the surrounding tissue.
This is accomplished by platelets which secrete large quanti-
ties of TSP and promote its incorporation into a fibrin ma-
trix. The TSP-rich fibrin matrix traps tumor cells in the
microvasculature and enables them to adhere, retract the en-
dothelium, and invade the surrounding stroma. We feel this
mechanism has great relevance to human cancer since pa-
tients with active metastatic disease have high levels of cir-
culating TSP (18). In support of this interpretation for our
model system are the recent studies of Lawler et al. (10)
which indicate that the type 1 repeats in chicken, mouse, and
humanare highly conserved. For example, mouse TSP con-tains two CSVTCG sequences and one CTVTCG sequence
whereas human TSP contains two CSVTCG sequences and
one CSTSCG sequence. Therefore, it is likely that CSVTCG
and related peptides could antagonize the adhesive activity
of endogenous mouse TSP .
To further establish that the sequences CSTSCG and
CSVTCG functioned as TSP adhesive domains, a polyclonal
antibody against CSTSCG was raised in a goat. The goat an-
tibody was affinity purified on a TSP column, tested for reac-
tivity against TSP by ELISA and Western immunoblot analy-
sis and evaluated for activity in adhesion, aggregation, and
metastasis assays. We found that anti-CSTSCG reacted with
TSP, and blocked cell adhesion, platelet aggregation, and tu-
mor cell metastasis. In the adhesion assay, even at the highest
antibody doses tested, some cells still attached and spread
on TSP suggesting that TSP must possess more than one cell
adhesion domain. In platelet aggregation assays, the anti-
body inhibited only the second or secretion phase ofplatelet
aggregation suggesting that platelet fibrinogen binding is not
affected. Finally, the antibody significantly blocked tumor
cell metastasis suggesting that the antibody interfered with
the activity of endogenous mouse TSP . Since mouse TSP
contains the related sequences, CTVTCG and CSVTCG
(10), one might expect that anti-CSTSCG would bind mouse
TSP and therefore block its activity. In fact, anti-CSTSCG
antibody reacted with both mouse and rat TSP by direct
ELISA supporting this proposed explanation for the anti-
metastatic activity of anti-CSTSCG.
In conclusion, these studies suggest that the conserved se-
quences homologous to CSVTCG in TSP and the malarial
proteins may function in the binding of ligand receptor pairs
that are fundamental in the cellular interactions governing
malarial infection, hemostasis, and tumor cell metastasis.
Elucidation of the receptors mediating these cellular events
will provide more insight into the functional role of these
conserved sequences.
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